Drugs / rAAV2-CBSB-hRPE65
rAAV2-CBSB-hRPE65
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00481546 | Jul 2007 → Dec 2016 | Leber congenital amaurosis | University of Pennsylvania | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAAV2-CBSB-hRPE65 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00481546 ↗ |
| Action | Restore | “adeno-associated virus-2-based RPE65 gene replacement therapy” PMID 18809924 ↗ Sep 2008 |
| Modality | Gene therapy (AAV / viral vector) | “A recombinant adeno-associated virus serotype 2 (rAAV2) vector, altered to carry the human RPE65 gene” PMID 18774912 ↗ Oct 2008 |